within Pharmacolibrary.Drugs.ATC.D;

model D05BB02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0029333333333333334,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.019,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00036666666666666667,
    Tlag           = 2400,            
    Vdp             = 0.0027,
    k12             = 5.3,
    k21             = 5.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05BB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acitretin is an oral retinoid primarily used for the treatment of severe psoriasis and other disorders of keratinization. It is a second-generation, synthetic analog of vitamin A. Acitretin has been approved for clinical use in several countries, but is contraindicated in women of childbearing age due to its high teratogenic potential.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of acitretin 50 mg.</p><h4>References</h4><ol><li><p>Heath, MS, et al., &amp; Feldman, SR (2018). Pharmacokinetics of tazarotene and acitretin in psoriasis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(9) 919–927. DOI:<a href=\"https://doi.org/10.1080/17425255.2018.1515198\">10.1080/17425255.2018.1515198</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30134735/\">https://pubmed.ncbi.nlm.nih.gov/30134735</a></p></li><li><p>Eichinger, JM, et al., &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 249–262. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2335310\">10.1080/17425255.2024.2335310</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38529623/\">https://pubmed.ncbi.nlm.nih.gov/38529623</a></p></li><li><p>Lee, CS, &amp; Li, K (2009). A review of acitretin for the treatment of psoriasis. <i>Expert opinion on drug safety</i> 8(6) 769–779. DOI:<a href=\"https://doi.org/10.1517/14740330903393732\">10.1517/14740330903393732</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19998529/\">https://pubmed.ncbi.nlm.nih.gov/19998529</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05BB02;
